Specifically, CYPRESS 1 enrolled patients with high PD-L1 expression (tumor proportion score [TPS] ≥ 50%), while CYPRESS 2 included patients with low or negative PD-L1 expression (TPS 0–49%) [119]. The gene discussed is CD274; the disease is neoplasm.